Program to Reduce Opioid Scripts Post-Surgery Worked for Thyroid Cancer Patients Post-surgical intervention may help to reduce the risk of opioid addiction and overdose Apr 29, 2022
New Guidelines Target Cancer Risk in Rare GI Syndromes Task force focuses on diagnosis, management of gastrointestinal hamartomatous polyposis syndromes Apr 28, 2022
When Free Flaps Fail Twice, Another Try Can Be Successful Second salvage attempt worked in 30% of cases Apr 28, 2022
Topical Antisepsis May Thwart SSIs in Upper Aerodigestive Tract Reconstruction Preoperative topical antisepsis mucosal preparation associated with 51% fewer infections Apr 28, 2022
Stop Calling It Cancer; AI Gets a Win in Bladder Cancer; Lack of Price Transparency News, features, and commentary about cancer-related issues Apr 22, 2022
Anti-CD39 Combination Therapy Promising in Gastric/GEJ Cancer Responses in a majority of patients, evidence of durability with TTX-030, chemoimmunotherapy Apr 14, 2022
PARP Inhibitor-Based Triplet Promising in Endometrial Cancer Olaparib/cyclophosphamide/metformin combo appears effective in older, heavily pretreated patients Apr 11, 2022
New Clue to Risk of Peritoneal Cancer After Prophylactic Salpingo-Oophorectomy Women with BRCA variant and serous tubal intraepithelial carcinoma had a 34-fold greater risk Apr 05, 2022
Black Patients More Often Get 'Substandard' Care for GI Cancers Retrospective study finds worse surgical outcomes, lower odds of receiving chemotherapy Apr 04, 2022
Triplet Induction Regimen Bests Doublet for Nasopharyngeal Carcinoma Three drugs reduced risk of disease failure, but longer follow-up needed to assess OS Mar 25, 2022
Artificial Sweeteners Not So Sweet When It Comes to Cancer Risk Consumption of certain sugar alternatives linked to a 13% higher risk of developing cancer Mar 24, 2022
Intraperitoneal Carboplatin Boosts PFS in Ovarian Cancer Should the gynecologic oncology community reconsider IP therapy? Mar 22, 2022
Lenvatinib Packaging for Endometrial Cancer Tied to $168 Million in Overspending Presenter breaks news at SGO that drug developer commits to overhauling dose reduction program Mar 20, 2022
Selinexor Proves Mettle in Advanced or Recurrent Endometrial Cancer Benefit was greatest among patients with wild-type p53 cancer in SIENDO trial Mar 20, 2022
Fecal Microbiome Markers Detect Pancreatic Cancer With 'High Accuracy' These markers need to be tested in a prospective cohort before clinical impact can be determined Mar 10, 2022
Robotic Hepatectomy Shows Benefits Over Laparoscopic Surgery Shorter hospital stay, similar perioperative outcomes in matched analysis Mar 10, 2022
Radioiodine for Low-Risk Thyroid Cancer: Yea or Nay? Randomized study finds no meaningful difference in events of abnormalities between groups Mar 09, 2022
Another Casualty of COVID-19: Evidence-Based Medicine Physician laments decline in research quality, critical appraisal during pandemic Mar 09, 2022
Cancer May Heighten Odds of Guillain-Barre Syndrome Link strongest with hematologic malignancies as well as prostate, breast, and respiratory cancers Mar 03, 2022
ARB-Cancer Link May Come Down to Cumulative Exposure Does a new paper resolve the conflicting safety data on the popular antihypertensives? Mar 02, 2022
Kids With IBD Need Close Monitoring as They Grow Up Meta-analysis confirms: substantially increased cancer risk in adulthood Mar 02, 2022
Novel Therapies Active in Head and Neck Cancers High response rate with oncolytic virus plus immunotherapy in cutaneous lesions Feb 28, 2022
AI Platform Near Perfect for Predicting Thyroid Malignancy High precision for T stage, extracapsular extension, BRAF mutation Feb 27, 2022
PD-L1 Inhibitor Fails to Meet PFS Target in Advanced Penile Cancer Atezolizumab did show some activity, with a 30% overall response rate Feb 22, 2022
Enfortumab Vedotin Promising in Neovadjuvant Therapy in Advanced Bladder Cancer Early-phase study offers 36% pCR in cisplatin-ineligible patients with muscle-invasive disease Feb 19, 2022
Ablating High-Grade Anal Lesions Thwarts Progression to Cancer Screening followed by aggressive therapy shows benefit in phase III ANCHOR study Feb 17, 2022
Sotorasib Impresses in Advanced Pancreatic Cancer ORR of 21% in heavily pretreated patients with a KRAS G12C mutation Feb 16, 2022
Women More Likely to Experience Severe Toxicity of Cancer Treatments Increased risk was particularly pronounced among those receiving immunotherapy Feb 14, 2022
Pembrolizumab Shows Promise in Advanced Anal Cancer PD-1 inhibitor may be an option for those who have no options Feb 11, 2022
Uterine Cancer Mortality Now Neck and Neck With Ovarian Cancer Advances in ovarian cancer, stagnation in uterine cancer, and "alarming" racial disparity Feb 09, 2022
Genetic Role of Alcohol-Cancer Link Strengthened In study from China, two common variants associated with lower risk of cancer in men Feb 01, 2022
When Strangers Deliver Bad News to Patients All too often, I end up giving prognoses to patients I barely know Jan 31, 2022
An 'Intriguing Failure' in Advanced, Pre-Treated GIST Second-line ripretinib unable to best sunitinib, but still had meaningful clinical activity Jan 26, 2022
Trial Data Confirm Heightened Risks With JAK Inhibitor May help patients and clinicians better weigh benefit against adverse effects Jan 26, 2022
Paclitaxel-Carboplatin Established as Standard of Care for Uterine Carcinosarcoma Median OS and PFS improved versus paclitaxel-ifosfamide Jan 25, 2022
GICS Roundup: PD-1 Inhibitor Yields 100% Response Rate in dMMR Rectal Cancer Plus: Promising activity in BRAF-mutant CRC, L-asparaginase drug falls short in pancreatic cancer Jan 24, 2022
Adagrasib Promising in KRAS-Mutant GI Cancers The KRAS G12C inhibitor showed a disease control rate of 100% in small study Jan 24, 2022
Survival Bump in Biliary Cancer With Immunotherapy Plus Chemotherapy Adding durvalumab boosts OS by 1.3 months, first survival improvement in a decade Jan 23, 2022
Potential New First-Line Options for Unresectable Hepatocellular Carcinoma Tremelimumab-durvalumab improves OS, single-agent durvalumab non-inferior to sorafenib Jan 22, 2022
Pre-Op Immunotherapy Combo Makes Headway in Select Gastric Cancers Plus, novel bispecific antibody tested as first-line therapy for advanced gastric/GEJ cancer Jan 21, 2022
